Compare Quest Diagnostics Inc (DGX) vs Hilton Hotels Corporation Common Stock (HLT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Hilton Hotels Corporation Common Stock — how do they compare? Quest Diagnostics Inc trades at $230.97 (market cap $25.48B), while Hilton Hotels Corporation Common Stock trades at $326.56 (market cap $72.76B). The key difference: Hilton Hotels Corporation Common Stock is far larger — about 2.9× Quest Diagnostics Inc's market cap, and Quest Diagnostics Inc pays the higher dividend (1.49%). Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Hilton Hotels Corporation Common Stock for 138 Days on average.
| DGX | HLT | |
|---|---|---|
Market Cap | $25.48B | $72.76B |
Volume | 941,866 | 1,148,634 |
Sector | Health | Consumer Cyclical |
52-Week High | $247.45 | $350.22 |
52-Week Low | $173.49 | $256.96 |
Typical Hold Time | 56 Days | 138 Days |
Enterprise Value | $31.23B | $85.78B |
Dividend Yield | 1.49% | 0.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.81, up 1.68% today, with a bullish earnings trend after beating EPS estimates for three consecutive quarters. The stock shows a mixed technical picture with a bearish overall signal but trades near key support at $228. Revenue growth accelerated to $11.04B in 2025, and the company maintains solid profitability with a 9.19% net income margin. Recent news highlights growth in consumer testing and a partnership with Apple Health, though Medicare reimbursement cuts pose a headwind.
The outlook is cautiously optimistic, supported by strong fundamentals and a consensus price target of $250 offering 8% upside. Key opportunities include demand for advanced diagnostics and AI adoption, while risks center on regulatory pressure and rising debt levels. Analyst sentiment is mixed with a slight hold bias, reflecting balanced growth prospects against near-term challenges.
Hilton Worldwide (HLT) trades at $323.29, up 0.87% today, with a bullish technical signal and strong institutional buying. Recent earnings beats and a consensus price target of $348.11 suggest upside potential. Revenue grew to $12.04B in 2025, with net income of $1.46B, though debt levels have risen. The company announced a Q3 2026 earnings release for October 27, 2026 (Business Wire, 2026-09-30).
The outlook is positive, supported by analyst buy ratings (57.14%) and robust travel demand. Key risks include high leverage and competitive pressures. Investors should monitor Q3 earnings for margin trends and debt management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Hilton Hotels Corporation Common Stock
Hilton Worldwide Holdings operates 1,074,791 rooms across its 18 brands addressing the midscale through luxury segments as of Dec. 31, 2021. Hampton and Hilton are the two largest brands by total room count at 28% and 21%, respectively, as of Dec. 31, 2021. Recent brands launched over the last few years include Home2, Curio, Canopy, Tru, and Tempo. Managed and franchised represent the vast majority of adjusted EBITDA, predominantly from the Americas regions.
Read more on HLT →
